Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 944-948, 2020.
Artigo
em Chinês
| WPRIM
| ID: wpr-880297
ABSTRACT
Prostate cancer (PCa) has become one of the common malignant diseases in elderly men, and its incidence is increasing year by year. Apart from surgery, radiotherapy and chemotherapy, immunotherapy, as with the programmed death receptor-1 (PD-1) or the programmed death ligand-1 (PD-L1) inhibitor, is a most promising new strategy for the treatment of PCa. PD-1 and PD-L1 inhibitors restore the activity of T cells by blocking the PD-1/PD-L1 signaling pathway in tumor cells, reverse the mechanism of tumor immune escape, recover the immune system and directly kill tumor cells. This review focuses on the current progress in the studies of PD-1 and PD-L1 inhibitors in the treatment of PCa.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias da Próstata
/
Transdução de Sinais
/
Antígeno B7-H1
/
Receptor de Morte Celular Programada 1
/
Inibidores de Checkpoint Imunológico
/
Imunoterapia
Limite:
Humanos
/
Masculino
Idioma:
Chinês
Revista:
National Journal of Andrology
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS